Letairis

Report
16 Pages
October 2018
Region: Global
Citeline
ID: 4775077

Drug Overview
Letairis (ambrisentan; Gilead/GlaxoSmithKline) is a selective endothelin type A receptor antagonist. Endothelin is a potent vasoconstrictor with mitogenic, hypertrophic, and pro-inflammatory properties. By preventing endothelin from binding to the endothelin receptor, Letairis blocks the receptor-mediated vasoconstriction of vascular smooth muscle cells.

Analyst Outlook
While second-to-market Letairis (ambrisentan; Gilead/GlaxoSmithKline) has not managed to exceed the historical peak sales of fellow endothelin receptor antagonist (ERA) Tracleer (bosentan; Johnson & Johnson), it has remained a market-leading drug. Given that Letairis will imminently face generic competition in the US in October 2018, with other markets shortly following, the drug has limited opportunities for further uptake within the pulmonary hypertension (PH) market. Nonetheless, Letairis is expected to continue to benefit from the increasing adoption of ERAs in combination with phosphodiesterase 5 (PDE5) inhibitors based on the AMBITION trial. This will counterbalance some generic erosion and aid in maintaining steady sales despite intensifying competition.

OVERVIEW

Drug Overview
Product Profiles

LIST OF FIGURES

Letairis : Pulmonary hypertension
Figure 1: Letairis for pulmonary hypertension – SWOT analysis
Figure 2: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 3: The authors drug assessment summary of Letairis for pulmonary hypertension
Figure 4: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES

Table 1: Letairis drug profile
Table 2: Letairis pivotal trial data in pulmonary arterial hypertension
Table 3: Letairis sales for pulmonary hypertension across the US, Japan, and five major EU markets, by country ($m),
–25

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9703EUR$10,000USD£8,368GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47546EUR$49,000USD£41,002GBP

Table of Contents

Related Topics

Related Reports

Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2028

Pulmonary Arterial Hypertension Market Growth Analysis Report - Latest Trends, Driving Factors and Key Players Research to 2030

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

Global Pulmonary Arterial Hypertension Market (2023-2028) Competitive Analysis, Impact of Covid-19, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis